JPMorgan Chase & Co. Downgrades Corteva (NYSE:CTVA) to Neutral

Corteva (NYSE:CTVA) was downgraded by research analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, MarketBeat reports. They currently have a $77.00 price objective on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 2.56% from the company’s current price.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group raised their price objective on shares of Corteva from $77.00 to $78.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Deutsche Bank Aktiengesellschaft decreased their price target on Corteva from $90.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Wolfe Research boosted their price target on shares of Corteva from $80.00 to $81.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Royal Bank Of Canada dropped their target price on shares of Corteva from $86.00 to $80.00 and set an “outperform” rating on the stock in a research report on Friday, October 17th. Finally, Wall Street Zen raised Corteva from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and an average target price of $79.68.

Corteva Stock Up 0.1%

Shares of NYSE:CTVA opened at $75.08 on Thursday. Corteva has a 52-week low of $53.40 and a 52-week high of $77.41. The company has a market capitalization of $50.73 billion, a PE ratio of 47.52, a price-to-earnings-growth ratio of 1.91 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.07 and a current ratio of 1.58. The company has a fifty day moving average of $68.60 and a 200-day moving average of $68.40.

Corteva (NYSE:CTVA) last posted its earnings results on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 8.97% and a net margin of 6.29%.The business’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period last year, the company earned $0.32 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities analysts predict that Corteva will post 2.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CTVA. Norges Bank bought a new position in Corteva in the 2nd quarter worth about $434,220,000. Perpetual Ltd increased its position in shares of Corteva by 78,688.5% in the fourth quarter. Perpetual Ltd now owns 2,615,779 shares of the company’s stock worth $175,336,000 after purchasing an additional 2,612,459 shares during the last quarter. Pacer Advisors Inc. raised its stake in Corteva by 4,007.1% in the third quarter. Pacer Advisors Inc. now owns 2,442,177 shares of the company’s stock valued at $165,164,000 after purchasing an additional 2,382,715 shares in the last quarter. WCM Investment Management LLC lifted its position in Corteva by 29.6% during the second quarter. WCM Investment Management LLC now owns 9,044,706 shares of the company’s stock valued at $672,836,000 after purchasing an additional 2,066,519 shares during the last quarter. Finally, Amundi grew its stake in Corteva by 125.3% in the 3rd quarter. Amundi now owns 3,415,554 shares of the company’s stock worth $219,620,000 after buying an additional 1,899,248 shares in the last quarter. Institutional investors own 81.54% of the company’s stock.

More Corteva News

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.45–$3.70, above the Street — a clear sign of confidence in profitable growth, margin expansion and controllable drivers. Strong 2H and Full Year 2025 Results (PR Newswire)
• Positive Sentiment: Company emphasized strong second half and full‑year 2025 performance, record free cash flow and operational discipline (product mix, cost saves, working‑capital efficiency) that support shareholder returns and reinvestment. Q4 Earnings Call Highlights (Yahoo Finance)
• Neutral Sentiment: Q4 EPS was roughly in line with consensus ($0.22 reported; some outlets note a slight beat vs. estimates), which de‑risks near‑term earnings surprises but does not offset revenue weakness. CTVA Surpasses Q4 Earnings Estimates (Zacks)
• Negative Sentiment: Q4 revenue missed expectations ($3.91B vs. ~$4.23B est.) — management cites seasonal timing shifts and weaker crop‑protection and seed demand as drivers, prompting downward pressure on the stock in after‑hours trading. Corteva misses quarterly sales estimates (MSN)
• Negative Sentiment: Market commentary highlights that the revenue shortfall was partly timing‑related but still widened losses on certain lines and sparked a near‑term selloff (reports of ~3% after‑hours decline). Monitor if demand softness persists into planting seasons. Corteva shares fall as seasonal timing shifts drive Q4 revenue miss (Investing.com) Corteva falls after-hours as Q4 revenue misses (Seeking Alpha)

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.